Overview

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Status:
Recruiting
Trial end date:
2046-12-31
Target enrollment:
Participant gender:
Summary
The trial investigates a stage-adapted (stage IIA or IIB) de-escalation of the standard treatments in the context of a multimodality treatment with chemo- and radiotherapy in seminoma patients. The goal is to safely de-escalate treatment while maintaining/enhancing efficacy, which is not a standard practice yet.
Phase:
Phase 2
Details
Lead Sponsor:
Swiss Group for Clinical Cancer Research
Collaborator:
German Testicular Cancer Study Group
Treatments:
Carboplatin
Cisplatin
Etoposide
Etoposide phosphate